Fragility Fractures of the Pelvis (FFP)

AO Innovation Translation Center420 enrolled

Overview

Prospective data will be collected in approximately 420 patients, above the age of 65, suffering from an FFP type fracture equal to or higher than type II, according to Rommens and Hofmann. Patients will be followed up according to the standard (routine) for up to 1 year after the treatment. Data collection will include underlying disease, treatment details, functional and patient reported outcomes (PRO)s, radiological outcomes, and anticipated or procedure-related adverse events (i.e. complications).

More in detail this registry has the following objectives: * To identify the difference in patient related outcome comparing the surgical and conservative treatment in patients suffering from an FFP with different levels of pelvic instability at different time points * To compare the rate of complications, morbidity and mortality between the different treatment modalities over the whole study period

Study Type

OBSERVATIONAL

Enrollment

420

Conditions

Pelvic Fracture

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 65 years or older at time of injury * Diagnosis, via CT scan as per standard of care, of FFP grade II or higher according to the Rommens and Hofmann classification (including fractures of the anterior pelvic ring involving the anterior lip of the acetabulum not regarded as the acetabular fractures) * Informed consent obtained, ie: * Ability to understand the content of the patient information/ICF * Willingness and ability to participate in the registry according to the standard of care in each clinic * Signed and dated Ethics Committee (EC)/ Institutional Review Board (IRB) approved written informed consent OR * Written consent provided according to the IRB/EC defined and approved procedures for patients who are not able to provide independent written informed consent Exclusion Criteria: * Pelvic fractures that do not meet the criteria of a fragility fracture (ie, high-energy trauma) * FFP type I fractures * Concomitant fractures of the acetabulum (except anterior lip of the acetabulum, see above) * Pathological fractures (ie, patients with malignant or metastatic diseases of the pelvis, infections) * Concomitant osteoporotic fractures outside of pelvis * Participation in any other medical device or medicinal product study within the previous month that could influence in opinion of the PI the results of the present registry

Locations (10)

University of Missouri

Columbia, Missouri, United States

RECRUITING

The Ottawa Hospital - Civic Campus

Ottawa, Canada

RECRUITING

University Medical Center Hamburg Eppendorf

Outcomes

Primary Outcomes

Demographics

Year of birth, Gender, Ethnicity, Height (cm) and Weight (kg) will be combined to report BMI in kg/m\^2

Time frame: Pre-treatment

Comorbidities

Concomitant diseases will be assessed using the Charlson Comorbidity Index (CCI). This score assesses the comorbidity level by considering both the number and severity of pre-defined comorbid conditions. It provides a weighted score of a patient's comorbidities which can be used to predict mortality rates. It is a 17-items questionnaire with score range from 0 to 37 points. It estimates the 10-year (or shorter) patient survival.

Time frame: Pre-treatment

Cognitive status

The MiniCog is a 3-minute instrument assessing cognitive impairment. It consists of two components, a 3-item recall test for memory and a simply scored clock drawing test. A total score ranges from 0 to 5. A score of zero, one or two out of five points in total, indicates a concern in cognitive functioning.

Time frame: Pre-treatment

Patient-reported outcomes: PROMIS Pain Interference

PROMIS (Patient-Reported Outcome Measurement Information System) Pain Interference (8 questions) assesses the impact of pain on common activities of daily life including social, cognitive, emotional, physical, and recreational aspects. The higher score represents a higher pain level.

Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

Patient-reported outcomes: PROMIS Physical Function

PROMIS Physical Function (10 questions) assesses self-reported capability of physical activities including instrumental activities of daily living. A higher score indicates a better self-reported capability.

Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

Central Contacts

Aleksandra Hodor

CONTACT

+41442002481 Aleksandra.hodor@aofoundation.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Parker Mobility Score

Parker Mobility Scale assess the patient's ability to perform indoor walking, outdoor walking, and shopping before the fracture. A score ranges between 0 and 3 (0 = not at all, 1 = with help from another person, 2 = with an aid, and 3 = no difficulty and no aid) for each function, resulting in a total score ranging from 0 (no walking ability at all) to 9 (fully independent).

Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

Modified Barthel index

The Barthel index is an ordinal scale and each performance item is rated on this scale with a given number of points assigned to each level or ranking. It uses 10 variables describing activities of daily living and mobility. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital.

Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

Residential status

The residential status will be documented at each visit during 1-year post-treatment phase.

Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

Mortality

Mortality will be assessed for 4 phases: * Perioperative mortality * Within the first 7 days after treatment (early-term) * Within the first 3 months after treatment (mid-term) * Until the last follow up (long-term mortality)

Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

Radiological outcomes

Position of the fracture fragments, to rule out secondary (additional) fracture fragments and displacement, or loosening of implants (Undisplaced, Displaced, Non-union with extensive callus)

Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

Anticipated treatment or condition-related adverse events (i.e. complications)

In this registry, only condition- or treatment-related events (ie complications) will be collected . Partially those events presuppose themselves: eg, re-admission for a surgical revision. In those cases, details on those different events will be collected.

Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)